Rho-associated coiled-coil containing protein kinase 1 and 2 (ROCK1/2)

Rho-associated coiled-coil containing protein kinases (ROCK1 and ROCK2) are vital serine/threonine kinases that function as primary downstream effectors of the small GTPase RhoA. They are central regulators of the actin-myosin cytoskeleton, influencing fundamental cellular processes such as morphology, motility, adhesion, and smooth muscle contraction (UniProt P70618, Q13464). Pathological overactivation of the ROCK pathway is implicated in various conditions, including cardiovascular diseases, glaucoma, and fibrotic disorders (PubMed: 26639446). Clinically, ROCK inhibitors such as Netarsudil and Ripasudil are utilized to treat glaucoma by enhancing aqueous humor outflow through the trabecular meshwork, while the ROCK2-selective inhibitor Belumosudil is approved for chronic graft-versus-host disease (FDA: NDA214783). ROCK1 and ROCK2 share significant structural homology but exhibit distinct tissue expressions, with ROCK1 being more prominent in non-neuronal tissues and ROCK2 being highly expressed in the brain, heart, and smooth muscle (StatPearls). Despite their therapeutic potential in oncology and neurology, systemic inhibition of ROCK can lead to significant hypotension due to vasodilation, necessitating careful drug design or localized delivery strategies (PubMed: 21903337).

Other names

ROCKRho-kinasep160ROCKROKp164ROCK

Competitive inhibition of the ATP-binding site of the ROCK enzymes, preventing the phosphorylation of downstream targets such as myosin light chain phosphatase and myosin light chain, leading to actin-myosin relaxation.